In addition, recently, a combinational treatment with targeted therapy against vascular endothelial growth factor (VEGF), or epidermal growth factor receptor (EGFR), has been proven to improve survival in patients with specific CRC subtypes. This evidence concerns the gene VEGFA and colorectal carcinoma.